Phase IV Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy (PRK) — PRO-037

Photorefractive Keratectomy Clinical Trial

Official title:
Phase IV Clinical Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo for Corneal Re-epithelialization After Photorefractive Keratectomy (PRK)

Status Completed

Clinical Trial Summary

Phase IV comparative, controlled, parallel group, open, randomized multicenter study to evaluate the efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo. Primary outcome measure is the time of corneal re-epithelialization after PRK surgery. Intervention includes administration of one of the experimental products quater per die (QID) for 14 days.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04704518
Study type	Interventional
Source	Laboratorios Sophia S.A de C.V.
Contact
Status	Completed
Phase	Phase 4
Start date	September 3, 2022
Completion date	December 22, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04281004` - Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy (PRK)	Phase 1/Phase 2
Recruiting	`NCT05313425` - Effect of Ectoine After Photorefractive Keratectomy (PRK).
Completed	`NCT00330798` - A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief	Phase 4
Recruiting	`NCT05477875` - Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control	Phase 2
Completed	`NCT05973253` - Evaluation of Efficacy and Safety of Topical 1% Medroxyprogesterone in the Corneal Epithelium Healing After PRK	Phase 2/Phase 3
Terminated	`NCT01381731` - A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)	Phase 2